A new study is putting two very different approaches to breast cancer risk assessment head to head, asking whether primary-care clinicians could identify more women under 50 who may benefit from specialist evaluation. Published in the British Journal of Cancer, the research compares the referral criteria recommended by the UK’s National Institute for Health and Care Excellence, commonly known as NICE, with BOADICEA, a multifactorial risk model designed to estimate an individual’s likelihood of developing breast cancer and the probability of carrying an inherited cancer-predisposition variant.
The comparison matters because breast cancer risk assessment in primary care often begins with a deceptively simple question: does a patient’s family history meet the threshold for referral? NICE guidance provides structured criteria based largely on patterns such as the number of relatives affected, their ages at diagnosis, and the presence of breast, ovarian, prostate or related cancers within a family. These rules are intended to be practical and safe, but they necessarily compress complex biological and genealogical information into a set of clinical decision points.
BOADICEA approaches the same problem as a mathematical risk calculation. The model was developed to combine multiple sources of evidence, including family history, inherited pathogenic variants in genes such as BRCA1, BRCA2 and other susceptibility genes, and broader genetic influences. In suitable versions of the model, these can be integrated with personal and reproductive factors and, where available, information such as polygenic risk scores. Instead of producing only a yes-or-no referral decision, BOADICEA can generate estimates of a woman’s future breast cancer risk and the likelihood that she carries a clinically important genetic variant.
The new analysis focuses specifically on women younger than 50 in primary care, a group for whom risk assessment can be particularly challenging. Breast cancer is less common at younger ages than later in life, yet an early diagnosis can be a warning sign of inherited susceptibility. A family history may also appear unremarkable when relatives are few, records are incomplete, family members are male, or individuals died before developing cancer. Conversely, a large family with several late-onset cancers may look alarming without necessarily indicating a highly penetrant inherited mutation.
That difference creates the possibility of disagreement between guideline-based assessment and multifactorial modelling. A woman who does not satisfy a conventional NICE referral threshold might nevertheless receive a meaningful risk estimate from BOADICEA if her available genetic and family information points toward elevated susceptibility. The reverse could also occur: a referral triggered by a recognizable family-history pattern might produce a lower calculated risk when the model accounts for additional details. Such discordance is central to the study’s clinical importance because every referral involves time, specialist capacity, genetic counselling resources and, for patients, potential anxiety and additional testing.
Risk models do not replace clinical judgement, and their output is only as reliable as the information entered. Family-history data can be incomplete or inaccurate, particularly when relatives have been adopted, estranged, diagnosed in different healthcare systems or recorded under nonspecific cancer labels. Genetic test results also require careful interpretation. A pathogenic variant can substantially change risk management, while a variant of uncertain significance should not be treated as proof of inherited disease. BOADICEA therefore functions best as a decision-support tool rather than an automated verdict.
The study’s primary-care setting is especially significant as health services move toward earlier and more personalized cancer prevention. General practitioners and other primary-care professionals are often the first to hear about a family history, but they may have limited time to construct detailed pedigrees or calculate lifetime cancer probabilities. A model that can be integrated into electronic records or a clinical risk platform could help standardize assessment, highlight missing information and identify patients who merit genetic counselling, enhanced surveillance or preventive discussion.
At the same time, a more sensitive approach must be balanced against the risk of over-referral. Sending every woman with a relative diagnosed with breast cancer to specialist services could overwhelm clinics and expose many people to investigations that are unlikely to change their care. The value of comparing NICE with BOADICEA is therefore not simply to determine which method produces more referrals. It is to examine whether the two systems identify the same women, where they diverge, and whether a combination of transparent guidelines and individualized risk prediction can improve the precision of primary-care triage.
The findings could influence how inherited breast cancer risk is recognized before a diagnosis occurs, particularly among younger women whose family histories fall into a grey zone. If multifactorial modelling identifies clinically important risk that guideline thresholds miss, it could support a broader, more data-driven route into specialist assessment. If the model adds little beyond existing criteria, its use might be better targeted to selected cases. Either outcome would help clarify how genetic information, family history and population-level guidance should work together as breast cancer prevention becomes increasingly personalized. The study by Frost, Ficorella, Berrington de Gonzalez and colleagues provides evidence for that debate and highlights a rapidly emerging question in modern medicine: can algorithms make inherited cancer risk assessment more accurate without making it less understandable?
Subject of Research: Comparison of NICE criteria and the BOADICEA multifactorial risk model for breast cancer risk assessment and referral among women under 50 in primary care.
Article Title: Comparison of NICE criteria with the BOADICEA multifactorial risk model to guide breast cancer risk assessment and referral amongst women under age 50 within primary care.
Article References: Frost, R., Ficorella, L., Berrington de Gonzalez, A. et al. “Comparison of NICE criteria with the BOADICEA multifactorial risk model to guide breast cancer risk assessment and referral amongst women under age 50 within primary care.” British Journal of Cancer (2026). https://doi.org/10.1038/s41416-026-03547-2
Image Credits: AI Generated
DOI: 10.1038/s41416-026-03547-2
Keywords: breast cancer, BOADICEA, NICE guidelines, genetic risk, inherited cancer, primary care, breast cancer risk assessment, genetic counselling, BRCA1, BRCA2, precision medicine
